Peramivir and its use in H1N1 influenza

Drugs of Today

Volumn 46, Issue 6, 2010, Pages 399-408

  Castillo, R ^a,b   Holland, L E ^b   Boltz, David A ^b  

^a ILLINOIS INSTITUTE OF TECHNOLOGY   (United States)

^b IIT RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; PERAMIVIR; PLACEBO; RAPIACTA; UNCLASSIFIED DRUG; ZANAMIVIR; ANTIVIRUS AGENT; CYCLOPENTANE DERIVATIVE; GUANIDINE DERIVATIVE;

ANTIVIRAL RESISTANCE; AREA UNDER THE CURVE; CLINICAL TRIAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG STRUCTURE; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; HUMAN; INFECTION PREVENTION; INFLUENZA A (H1N1); NONHUMAN; REVIEW; SINGLE DRUG DOSE; VIRUS TITRATION; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; EMERGENCY; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; INFLUENZA, HUMAN; UNITED STATES; VIROLOGY;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; CYCLOPENTANES; EMERGENCIES; GUANIDINES; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA, HUMAN; OSELTAMIVIR; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77955447704     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2010.46.6.1459659     Document Type: Review

References (69)

1. Garten, R.J., Davis, C.T., Russell, C.A. et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009, 325(5937): 197-201.
2. Igarashi, M., Ito, K., Yoshida, R., Tomabechi, D., Kida, H., Takada, A. Predicting the antigenic structure of the pandemic (H1N1) 2009 influenza virus hemagglutinin. PLoS One 2010, 5(1): e8553.
3. Hancock, K., Veguilla, V., Lu, X. et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009, 361(20): 1945-52.
4. World Health Organization (WHO). Pandemic influenza vaccine manufacturing process and timeline (online). Available from http://www.who.int/csr/disease/ swineflu/notes/h1n1-vaccine-20090806/en/index.html (Accessed January 25 2010).
5. Wang, C., Takeuchi, K., Pinto, L.H., Lamb, R.A. Ion channel activity of influenza A virus M2 protein: Characterization of the amantadine block. J Virol 1993, 67(9): 5585-94.
6. Maugh, T.H. Amantadine: An alternative for prevention of influenza. Science 1976, 192(4235): 130-1.
7. Weinstock, D.M., Gubareva, L.V., Zuccotti, G. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N Engl J Med 2003, 348(9): 867-8.
8. Shiraishi, K., Mitamura, K., Sakai-Tagawa, Y., Goto, H., Sugaya, N., Kawaoka, Y. High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. J Infect Dis 2003, 188(1): 57-61.
9. Bright, R.A., Medina, M.J., Xu, X. et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: A cause for concern. Lancet 2005, 366(9492): 1175-81.
10. Centers for Disease Control and Prevention (CDC). Influenza activity - United States and worldwide, 2007-08 season. MMWR 2008, 57(25): 692-7.
11. Deyde, V.M., Sheu, T.G., Trujillo, A.A., Okomo-Adhiambo, M., Garten, R., Klimov, A. I., Gubareva, L.V. Detection of molecular markers of drug resistance in the 2009 pandemic influenza A (H1N1) viruses using pyrosequencing. Antimicrob Agents Chemother 2010, 54(3): 11002-10.
12. Hayden, F.G. Amantadine and rimantadine - Clinical aspects. In: Antiviral Drug Resistance. Richman, D.D. (Eds). New York: John Wiley and Sons, Inc., 1996, 59-77.
13. Nelson, M.I., Simonsen, L., Viboud, C., Miller, M.A., Holmes, E.C. The origin and global emergence of adamantane resistant A/H3N2 influenza viruses. Virology 2009, 388(2): 270-8.
14. Gubareva, L.V., Kaiser, L., Hayden, F.G. Influenza virus neuraminidase inhibitors. Lancet 2000, 355(9206): 827-35.
15. U.S. Food and Drug Administration. Emergency use authorization of peramivir iv fact sheet for health care providers [online]. Available from http://www.fda.gov/downloads/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/UCM187811.pdf (Accessed January 21 2010).
16. Dharan, N.J., Gubareva, L.V., Meyer, J.J. et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 2009, 301(10): 1034-41.
17. Hurt, A.C., Ernest, J., Deng, Y.M. et al. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res 2009, 83(1): 90-3.
18. Moscona, A. Global transmission of oseltamivir-resistant influenza. N Engl J Med 2009, 360(10): 953-6.
19. Chen, H., Cheung, C.L., Tai, H. et al. Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus, Hong Kong, China. Emerg Infect Dis 2009, 15(12): 1970-2.
20. Deyde, V.M., Xu, X., Bright, R.A. et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis 2007, 196(2): 249-57.
21. Le, Q.M., Wertheim, H.F., Tran, N.D., van Doom, H.R., Nguyen, T.H., Horby, P. A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. N Engl J Med 2010, 362(1): 86-7.
22. Babu, Y.S., Chand, P., Bantia, S. et al. BCX-1812 (RWJ-270201): Discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J Med Chem 2000, 43(19): 3482-6.
23. Russell, R.J., Haire, L.F., Stevens, D.J. et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 2006, 443(7107): 45-9.
24. Bantia, S., Arnold, C.S., Parker, C.D., Upshaw, R., Chand, P. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res 2006, 69(1): 39-45.
25. Nguyen, H.T., Le, L., Truong, T.N. Top-hits for H1N1pdm identified by virtual screening using ensemble-based docking. PLoS Curr Influenza 2009, RRN1030.
26. Collins, P.J., Haire, L.F., Lin, Y.P. et al. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 2008, 453(7199): 1258-61.
27. Hurt, A.C., Holien, J.K., Parker, M., Kelso, A., Barr, I.G. Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J Virol 2009, 83(20): 10366-73.
28. Drusano, G.L., Preston, S.L., Smee, D., Bush, K., Bailey, K., Sidwell, R.W. Pharmacodynamic evaluation of RWJ-270201, a novel neuraminidase inhibitor, in a lethal murine model of influenza predicts efficacy for once-daily dosing. Antimicrob Agents Chemother 2001, 45(7): 2115-8.
29. Sweet, C., Jakeman, K.J., Bush, K. et al. Oral administration of cyclopentane neuraminidase inhibitors protects ferrets against influenza virus infection. Antimicrob Agents Chemother 2002, 46(4): 996-1004.
30. Yun, N.E., Linde, N.S, Zacks, M.A. et al. Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1). Virology 2008, 374(1): 198-209.
31. Young, D., Fowler, C., Bush, K. RWJ-270201 (BCX-1812): A novel neuraminidase inhibitor for influenza. Philos Trans R Soc London 2001, 356(1416): 1905-13.
32. BioCryst Pharmaceuticals I. Biocryst presents phase I peramivir data at the options for the control of influenza conference [online]. Available from http://investor.shareholder.com/biocryst/releasedetail.cfm?ReleaseID=249625 (Accessed January 20 2010).
33. BioCryst Pharmaceuticals. Biocryst announces presentation of peramivir human clinical data at the 46th annual ICAAC meeting [online]. Available from http://investor.shareholder.com/biocryst/releasedetail.cfm?ReleaseID=212634 (Accessed January 20 2010).
34. Sidwell, R.W., Smee, D.F. In vitro and in vivo assay systems for study of influenza virus inhibitors. Antiviral Res 2000, 48(1): 1-16.
35. Sidwelt, R.W., Smee, D.F., Bailey, K.W., Burger, R.A. Primary immune system effects of the orally administered cyclopentane neuraminidase inhibitor RWJ-270201 in influenza virus-infected mice. Int Immunopharmacol 2001, 1(6): 1211-8.
36. Barroso, L., Treanor, J., Gubareva, L., Hayden, F.G. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment. Antivir Ther 2005, 10(8): 901-10.
37. Subbarao, K., Klimov, A., Katz, J. et al. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 1998, 279(5349): 393-6.
38. Peiris, M., Yuen, K.Y., Leung, C.W. et al. Human infection with influenza H9N2. Lancet 1999, 354(9182): 916-7.
39. Bantia, S., Parker, C.D., Ananth, S.L. et al. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob Agents Chemother 2001, 45(4): 1162-7.
40. Smee, D.F., Huffman, J.H., Morrison, A.C., Barnard, D.L., Sidwell, R.W. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrob Agents Chemother 2001, 45(3): 743-8.
41. Mishin, V.P., Hayden, F.G., Signorelli, K.L., Gubareva, L.V. Evaluation of methyl inoslne monophosphate (MIMP) and peramivir activities in a murine model of lethal influenza A virus infection. Antiviral Res 2006, 71(1): 64-8.
42. Sidwell, R.W., Smee, D.F., Huffman, J.H., Barnard, D.L., Bailey, K.W., Morrey, J.D., Babu, Y.S. In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201. Antimicrob Agents Chemother 2001, 45(3): 749-57.
43. Govorkova, E.A., Leneva, I.A., Goloubeva, O.G., Bush, K., Webster, R.G. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob Agents Chemother 2001, 45(10): 2723-32.
44. Boltz, D.A., Ilyushina, N.A., Arnold, C.S., Babu, Y.S., Webster, R.G., Govorkova, E.A. Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice. Antiviral Res 2008, 80(2): 150-7.
45. Iyer, G.R., Liao, S., Massarella, J. Population analysis of the pharmacokinetics and pharmacodynamics of RWJ-270201 (BCX-1812) in treating experimental influenza A and B virus in healthy volunteers. AAPS PharmSci 2002, 4(4): E22.
46. BioCryst Pharmaceuticals. BioCryst reports preliminary results from a phase II clinical trial of peramivir in subjects with acute influenza (online). Available from http://investor.shareholder.com/biocryst/releasedetail.cfm? ReleaseID=264815 (Accessed January 20 2010).
47. BioCryst Pharmaceuticals. BioCryst updates peramivir clinical development plan (online). Available from http://investor.shareholder.com/biocryst/ releasedetail.cfm?ReleaseID=289253 (Accessed January 20 2010).
48. BioCryst Pharmaceuticals. BioCryst provides peramivir update and reports first quarter 2009 financial results (online). Available from http://investor.shareholder.com/biocryst/releasedetait.cfm?ReleaseID=382718 (Accessed January 20 2010).
49. Beigel, J., Harman, L.A., Collis, P.J. et al. Pharmacokinetic and safety evaluations of escalating doses of peramivir administered intravenously in healthy volunteers. 47th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 17-20, Chicago) 2007, Abst A-1408.
50. Collis, P.J., Harman, A., Kilpatrick, J.M., Denoia, E., Mead, E., Noonan, P., Alexander, W.J. A placebo-controlled evaluation of the safety and pharmacokinetics of multiple-dose intravenous administration of peramivir to healthy elderly subjects. 47th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 17-20, Chicago) 2007, Abst A-1409.
51. Alexander, W.J., Harman, A., Collis, P.J., Elder, J., Kilpatrick, J.M., Atiee, G., Mead, E. Nasal and pharyngeal concentrations of peramivir following intramuscular and intravenous administration in healthy volunteers.47th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 17-20, Chicago) 2007, Abst A-1410.
52. Ison, M.G., McGeer, A.J., Hui, D.S. et al. Safety and efficacy of multiple-day treatment with intravenous peramivir or oral oseltamivir in hospitalized adults with acute influenza. 11th Int Symp Respir Viral Infect (February 19-22, Bangkok) 2009, Abst.
53. Kohno, S., Yen, M.Y., Cheong, H.J. et al. Single-intravenous peramivir vs. oral oseltamivir to treat acute, uncomplicated influenza in the outpatient setting: A phase III randomized, double-blind trial. 49th lntersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 12-15, San Francisco) 2009, Abst V-537a.
54. BioCryst Pharmaceuticals. BioCryst Pharmaceuticals reports positive results of Shionogi & Co. Sponsored phase 3 studies of i.v. peramivir for influenza (online). Available from http://investor.shareholder.com/biocryst/ ReleaseDetail.cfm?ReleaseID=397310 (Accessed January 20 2010).
55. BioCryst Pharmaceuticals. BioCryst's partner Shionogi launches peramivir in Japan under the name 'RAPIACTA' (online). Available from http://investor. shareholder.com/biocryst/releasedetail.cfm?ReleaseID=440218 (Accessed March 25 2010).
56. Shionogi and Co. Ltd. Shionogi files an additional application for pediatric use of "RAPIACTA®"a novel anti-viral drug for influenza (online). Available from http://www.shionogi.co.jp/ir/news/detail/100215.pdf (Accessed March 28 2010).
57. Baz, M., Abed, Y., Boivin, G. Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir. Antiviral Res 2007, 74(2): 159-62.
58. Hurt, A.C., Holien, J.K., Barr, I.G. In vitro generation of neuraminidase inhibitor resistance in A (H5N1) influenza viruses. Antimicrob Agents Chemother 2009, 53(10): 4433-40.
59. Gubareva, L.V., Webster, R.G., Hayden, F.G. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Chemother 2001, 45(12): 3403-8.
60. Memoli, M.J., Hrabal, R.J., Hassantoufighi, A., Eichelberger, M.C., Taubenberger, J.K. Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin Infect Dis 2010, 50(9): 1252-5.
61. Cheng, P.K., To, A.P., Leung, T.W., Leung, P.C., Lee, C.W., Lim, W.W. Oseltamivir- and amantadine-resistant influenza virus A (H1N1). Emerg Infect Dis 2010, 16(1): 155-6.
62. Baz, M., Abed, Y., Papenburg, J., Bouhy, X., Hamelin, M.E., Boivin, G. Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. N Engl J Med 2009, 361(23): 2296-7.
63. Monto, A.S., McKimm-Breschkin, J.L, Macken, C. et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 2006, 50(7): 2395-402.
64. Sheu, T.G., Deyde, V.M., Okomo-Adhiambo, M. et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 2008, 52(9): 3284-92.
65. Meijer, A., Lackenby, A., Hungnes, O. et al. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 Season. Emerg Infect Dis 2009, 15(4): 552-60.
66. Centers for Disease Control and Prevention (CDC). 2009-2010 Influenza Season Week 3 ending January 23, 2010 (online). Available from http://www.cdc.gov/flu/weekly/ (Accessed January 28 2010).
67. World Health Organization (WHO). Pandemic (H1N1) 2009 - update 94 (online). Available from http://www.who.int/csr/don/2010-04-01/en/index.html (Accessed April 1 2010).
68. Swan, S., Marbury, T., Smith, W. et al. Safety and pharmacokinetics of peramivir following intravenous administration in subjects with renal impairment. 47th Annu Meet Infect Dis Soc Am (IDSA) (Oct 29-Nov 1, Philadelphia) 2009, Abst 623.
69. Birnkrant, D., Cox, E. The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med 2009, 361(23): 2204-7.